5-amino-1mq and cd38 inhibitor synergy nad+ The Pharmacology of CD38/NADase: An emerging target for cancer aging diseases Dysregulation of Niacin-Derived NAD+ Salvage
Dysregulation of Niacin Derived NAD+ Salvage Pathway Markers (CD38, NAMPT, SIRT1) Across Albuminuria Stages in Type 2 Diabetes Inhibition of CD38 by 78c Enhanced NAD+, Alleviated Inflammation, and Decreased Oxidative Stress in Old Murine Macrophages Induced by Oral Pathogens Discovery of a First in Class CD38 Inhibitor for the Treatment of Mitochondrial Myopathy Journal of Medicinal Chemistry SLC25A51 decouples the mitochondrial NAD+ NADH ratio to control proliferation of AML cells: Cell Metabolism
Pay in 4 interest-free payments of $7.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8


